View Older Stories View More Recent Stories
-
T-knife Therapeutics Presents Preclinical Data on PRAME-Targeted TK-6302 Highlighting its Potential as a Promising, Category-leading Therapy at the Society for Immunotherapy of Cancer (SITC) Annual Me
-
RANI Therapeutics secures $1.085 billion Chugai deal and $60.3 million funding
-
Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update
-
Form SCHEDULE 13D/A Werewolf Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates
-
Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights
-
C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
-
Azalea Therapeutics Launches with $82 Million Financing to Redefine Precision Genomic Medicines by Engineering Cells Directly Inside Each Patient
-
Form SCHEDULE 13D/A 89bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
CellCentric to Host Investor Event and Present Dose Optimization Data from Phase 2 Study of Inobrodib for Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting
-
Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G Rani Therapeutics Holdin Filed by: RA CAPITAL MANAGEMENT, L.P.
-
T-knife Therapeutics Announces Four Upcoming Data Presentations on PRAME-Targeted TK-6302 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
-
Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G Lexeo Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Hemab Therapeutics Announces $157 Million Series C Financing to Advance Next-Generation Treatments for Underserved Bleeding Disorders
-
Form SCHEDULE 13G C4 Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Rani Therapeutics adds two directors, closes $60.3 million funding
-
Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors
-
Rani Therapeutics raises $60.3 million in oversubscribed private placement
-
Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules
-
VitriVax Raises $17.25 Million Series B Financing to Advance Vaccine Formulation Platform
-
Electra Therapeutics Announces $183 Million Series C Financing to Advance First-in-Class SIRP-Targeted Therapies for Immune Disorders and Cancer
-
Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Exploring the Next Era of Cell & Gene Therapy with Nobel Laureate in London
-
Rani Therapeutics raises $60.3 million in oversubscribed private placement
-
Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules
-
Rani Therapeutics secures $1.085 billion collaboration deal with Chugai
-
Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurre
-
Form SCHEDULE 13G Jade Biosciences, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
C4 Therapeutics prices $125 million stock offering
-
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
-
Adcytherix Raises EUR 105M Series A to Accelerate Breakthrough Antibody-Drug Conjugate Pipeline with Strategic Focus on Novel Payloads
-
Radence expands concierge membership to detect and prevent disease before it occurs
-
Form SCHEDULE 13G PALISADE BIO, INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
T-knife Therapeutics Presents Preclinical Data Highlighting the Transformative Potential of the MyT™ Platform to Discover and Develop Next-Generation TCR Therapies to Treat Solid Tumors at the Europ
-
T-knife Therapeutics Presents Preclinical Data Highlighting the Transformative Potential of the MyT™ Platform to Discover and Develop Next-Generation TCR Therapies to Treat Solid Tumors at the Europ
-
Jade Biosciences raises $135 million in private placement
-
Jade Biosciences Announces $135 Million Private Placement
-
Form SCHEDULE 13D SAB Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Ovid Therapeutics raises up to $175 million in private placement
-
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
-
Palisade Bio closes $138 million public offering to fund drug trial
-
Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option
-
Form SCHEDULE 13D/A ARS Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Drugmakers pressured with Trump tariffs after price‑cut talks faltered
-
Form SCHEDULE 13D/A PepGen Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
RA Capital Management Funds Expansion of ARS Pharma Commercial Activity, Expands Portfolio of Financing Solutions for Innovative Healthcare Companies
-
Star Therapeutics Announces Oversubscribed $125 Million Series D Financing
-
ARS Pharmaceuticals secures $250 million loan facility for neffy expansion
